COLLEEN MARSHALL: Open Payments
NPI 1851837900 · ENOLA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,160 in 117 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $310 · 2025 $10,160
Consulting: $4,960Food & beverage: $2,719Travel & lodging: $2,481
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 67 | $8,917 |
| Otsuka America Pharmaceutical, Inc. | 17 | $392 |
| Neurocrine BioSciences, Inc. | 6 | $221 |
| Alkermes, Inc. | 7 | $153 |
| Teva Pharmaceuticals USA, Inc. | 3 | $150 |
| E.R. Squibb & Sons, L.L.C. | 8 | $138 |
| Lundbeck LLC | 4 | $80 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
Products named: CAPLYTA, REXULTI, INGREZZA, LYBALVI, AUSTEDO XR, COBENFY, ABILIFY MAINTENA, Auvelity.
Industry payments across PA — which companies pay providers there.
